Ajinomoto Co., Ltd.

Hiroyuki Matsueda

Toshihiro Hatanaka

Nobuo Kondo

Koji Ohsumi

Katsumi Maezono

Yoko Kageyama

Takashi Yamamoto

Takashi Umemura

Akiko Onuki

Seiji Niwa

Yoko Masuzawa

Ryusuke Hirama

Takashi Nakano

Kunisuke Izawa

Masahiko Kurauchi

Takao Ikenoue

Yukio Iino

Akiyo Yamazaki

Fumio Ohta

Yoshimasa Hagiwara

Nozomu Ishida

Morikazu Kito

Masanobu Yatagai

Akira Takahara

Tomoko Takeda

Yukitsugu Ono

Hajime Koganei

Seiji Ohno

Shinichiro Takahashi

Masaki Naito

Yuki Kajigaya

Isao Arai

Masako Hagihara

Chika Nakanishi

Yoko Sugawara

The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic effect of diabetes mellitus as never been obtained by the hypoglycemic agents of the related art can be achieved.

Prophylactic and therapeutic agent of diabetes mellitus

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine. 

Pyrazole derivatives and diabetic medicine containing them

An agent for increasing the sugar-transporting capacity and an agent for preventing and/or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which contains a lactam compound or a pharmaceutically acceptable salt thereof as the active ingredient.

Lactam compounds and pharmaceutical use thereof

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine 

Compounds having a selective N-type calcium channel antagonistic activity are provided. Dihydropyridine derivatives represented by the following formula: analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel, and they are used as therapeutic agents for various diseases relating to N-type calcium channel.

Dihydropyridine derivatives

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.

The present invention relates to a novel process for preparing an aminostilbene derivative, which is important as an active component of anticancer drugs or an intermediate for preparation thereof, as well as methods of producing the same.

Process for preparing aminostilbene derivatives

The present invention relates to pyrazole derivatives represented by the following formulas and analogues thereof, which can be used for a therapeutic agent for diabetes.

N-substituted pyrazole-O-glycoside derivatives and therapeutic agent for diabetes containing the same

A Type IV crystal of (Z)-N-&lsqb;2-methoxy-5-&lsqb;2-(3,4,5-trimethoxyphenyl)vinyl&rsqb;phenyl&rsqb;-L-serinamide hydrochloride, which can be produced by crystallization using a solvent containing water at 2% by weight at the maximum and which has a X ray powder diffraction pattern containing peaks at least at 13.4&deg;, 18.7&deg;, 19.4&deg;, and 22.5&deg; (2&thgr;), is provided. This compound is useful as an effective ingredient for a carcinostatic agent. The crystal of the present invention has excellent properties desirable from the standpoint of the production of medicinal products, i.e., reduced water adsorption and extremely high stability to water. Also provided are a method for producing the Type IV crystal thereof and a method for use of the crystal.

Stilbene derivative crystal and method for producing the same

Provided is an industrially useful process for producing an optically active 2-hydroxy-4-arylbutyric acid or its ester. An optically active acyloxysuccinic anhydride is reacted with an aromatic compound in the presence of a Lewis acid to produce an optically active 2-acyloxy-4-oxo-4-arylbutyric acid. The 2-acyloxy-4-oxo-4-arylbutyric acid is converted to an optically active 2-acyloxy-4-arylbutyric acid through catalytic reduction. The 2-acyloxy-4-arylbutyric acid is hydrolyzed in the presence of an acid or an alkali to produce an optically active 2-hydroxy-4-arylbutyric acid. The 2-hydroxy-4-arylbutyric acid is reacted with an alcohol in the presence of an acid to produce an optically active 2-hydroxy-4-arylbutyric acid ester.

Process for producing optically active 2-hydroxy-4-arylbutyric acid or its ester

Process for producing optically active 2-hydroxy-4-arylbutyric acid or

Growing community of inventors

Kawasaki, Japan

Hiroyuki Matsueda